T Cell News and Research

Latest T Cell News and Research

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

Specific forms of lymphoma create their own survival niche

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors.

7 Jun 2011

Silencing two microRNAs may help treat age-related macular degeneration

Blocking two tiny molecules of RNA - a chemical cousin of DNA - appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, UT Southwestern Medical Center researchers have found.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Researchers reveal surprising link between cell's skeleton and organ size

A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.

7 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois.

6 Jun 2011

Senescent melanoma cells express an inflammatory secretome

Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In this paper, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile ("secretome") that can ultimately promote metastasis and contribute to melanoma relapse.

6 Jun 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

6 Jun 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego™, for the treatment of Stage IV metastatic melanoma.

6 Jun 2011

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

Emergent BioSolutions Inc. announced today that it has acquired from TenX BioPharma, Inc. the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas.

6 Jun 2011

New gene therapy may cure Type 1 diabetes

An experimental cure for Type 1 diabetes has a nearly 80 percent success rate in curing diabetic mice. The results, to be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston, offer possible hope of curing a disease that affects 3 million Americans.

6 Jun 2011

Light exposure can enhance brain's visual circuits

Any parent knows that newborns still have a lot of neurological work to do to attain fully acute vision. In a wide variety of nascent animals, genes provide them with only a rough wiring plan and then leave it to the developing nervous system to do its own finish work.

6 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

Global gene therapy market to reach $300 million by 2015

The global gene therapy market is expected to grow to over $300 million by 2015, according to a new report available on companiesandmarkets.com. The gene therapy market will grow further driven by the human genome project, the increasing incidence of cancer and other critical diseases.

6 Jun 2011

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Following the conclusion of a series of meetings with the United States Food and Drug Administration (FDA), GTx, Inc. announced today the clinical trial design for the two Phase III Ostarine registration studies for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer (NSCLC).

6 Jun 2011

Azellon receives MHRA approval to initiate stem cell bandage clinical trial in torn meniscal cartilage

Millions of people with knee injuries could benefit from a new type of stem cell bandage treatment if clinical trials are successful. The world's first clinical trial for the treatment of patients with torn meniscal cartilage has received approval from the UK regulatory agency, the MHRA1, to commence.

6 Jun 2011

T Cell News and Research

Latest T Cell News and Research

Scientists discover key molecule that targets tumour blood vessels

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Specific forms of lymphoma create their own survival niche

Silencing two microRNAs may help treat age-related macular degeneration

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Researchers reveal surprising link between cell's skeleton and organ size

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Onconova to initiate ESTYBON Phase II/III study in pancreatic cancer

Senescent melanoma cells express an inflammatory secretome

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Genesis Biopharma expands clinical focus to develop Contego for Stage IV metastatic melanoma

TenX BioPharma grants Emergent BioSolutions rights to zanolimumab

New gene therapy may cure Type 1 diabetes

Light exposure can enhance brain's visual circuits

Cancer risk assessment in Lynch syndrome

Global gene therapy market to reach $300 million by 2015

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Azellon receives MHRA approval to initiate stem cell bandage clinical trial in torn meniscal cartilage

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Newsletters you may be interested in